Companies /Healthcare

Johnson & Johnson

NYSE: JNJ Drug Manufacturers - General
$270.01
▲ $2.93 (+1.10%) today
Markets open · 10:08am ET

JNJ Coverage

Page 92
10:17am ET
Health and Healthcare

For Boston Scientific And JNJ, The Stent Stats Get Worse

"William O’Neill, dean of clinical affairs at University of Miami’sMiller School of Medicine, says stent-patient traffic is beginning topick up in South Florida. Still, restoring luster to the popular deviceis likely to…

Douglas A. McIntyre
7:03am ET
Investing

Johnson & Johnson’s (JNJ) Good Quarter

Johnson & Johnson (JNJ) announced third-quarter sales of $15.0 billion, an increase of 12.7% as compared to the third quarter of 2006.Net earnings and diluted earnings per share for the third quarter…

JNJ
Douglas A. McIntyre
3:10pm ET
Health and Healthcare

Medtronic (MDT): The Stent Business Gets Worse

Medtronic (MDT) has decided to get into the stent business, making the little mesh tubes that keep arteries open. It is a perverse selection because Boston Scientific (BSX) and Johnson & Johnson…

Douglas A. McIntyre
5:37am ET
Health and Healthcare

For Boston Scientific (BSX) Stent News Gets More Complex

Stent sales for Boston Scientific (BSX) and Johnson & Johnson (JNJ) have taken a big drop since research began to emerge that the products could cause heart problems. There have been several…

Douglas A. McIntyre
7:32am ET
Health and Healthcare

ISIS Scores On J&J Collaboration & Milestones (ISIS, JNJ)

ISIS Pharmaceuticals Inc. (NASDAQ:ISIS) is trading up pre-market on new that it entered a broad collaboration with Ortho-McNeil, a Johnson & Johnson (NYSE:JNJ) unit, for discovery, development and commercialization of antisense drugs…

JNJ
Douglas A. McIntyre
7:25am ET
Health and Healthcare

Amgen Set To Run (AMGN, JNJ, BIIB)

Amgen Inc. (NASDAQ:AMGN) is seeing shares trade up another 2% pre-market after yesterday’s decision where an FDA panel rejected a proposal to set a specific target for red blood-cell levels in kidney-failure…

Douglas A. McIntyre